arrow
S

Shu Cao

stanford university school of medicine
H指数:27
被引数:2,367

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Peanut allergy oral immunotherapy drives single-cell multi-omic changes in peanut-reactive T cells associated with sustained unresponsiveness

花生过敏口服免疫疗法驱动与持续无反应性相关的花生反应性T细胞的单细胞多体变化

2025-11-040
OAAI
Trends in allergen-reactive CRTH2+ T cells and TARC associated with successful outcomes in a phase 2 cashew oral immunotherapy study

与一个2期腰果口服免疫疗法研究成功结局相关的过敏原反应性CRTH2+ T细胞和TARC的趋势

2025-10-220
OAAI
Shrimp oral immunotherapy outcomes in the phase 2 clinical trial: MOTIF

虾口服免疫疗法在2期临床试验中的结果:MOTIF

2025-07-220
OA
Combining avidin with CD63 improves basophil activation test accuracy in classifying peanut allergy

抗生物素蛋白与CD63结合可提高花生过敏分类中嗜碱性粒细胞激活测试的准确性

2023-11-023
PRE
Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19

新型冠状病毒肺炎的哮喘表型、相关合并症和长期症状

2021-06-1950
OAAI
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients

随机生存森林识别具有多态性的预测KRAS突变型和KRAS野生型转移性结直肠癌患者生存的途径

2021-06-094
OAAI
Gastrointestinal Eosinophil Responses in a Longitudinal, Randomized Trial of Peanut Oral Immunotherapy
2021-06-0143
OAAI
RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC

RNA结合蛋白多态性作为预测转移性结直肠癌预后的新生物标志物: 来自TRIBE,FIRE-3和MAVERICC的荟萃分析

2021-03-301
OA